<table sstyle="width:80%" align="center" border=1>
<tr>
<th>mv</th>
<th>dw</th>
<th>HMMCrowd</th>
</tr>
<tr>
<td width=33%>
[6, 8] serum lipoproteins<br>[9, 14] metabolites of arachidonic acid:<br>[116, 123] plasma 6-keto-prostaglandin F1 alpha concentration<br>[125, 129] serum thromboxane B2 concentration<br>[148, 155] plasma 6-keto-prostaglandin F1 alpha concentration<br>[161, 165] serum HDL2 cholesterol concentration<br></td>
<td width=33%>
[6, 8] serum lipoproteins<br>[9, 14] metabolites of arachidonic acid:<br>[32, 35] biochemical risk factors<br>[36, 39] ischaemic heart disease<br>[67, 70] serum cholesterol concentrations<br>[76, 84] high density lipoprotein subfraction two (HDL2)<br>[116, 123] plasma 6-keto-prostaglandin F1 alpha concentration<br>[125, 129] serum thromboxane B2 concentration<br>[148, 155] plasma 6-keto-prostaglandin F1 alpha concentration<br>[161, 165] serum HDL2 cholesterol concentration<br>[182, 184] cholesterol distribution<br>[198, 204] circulating metabolites of arachidonic acid.<br></td>
<td width=33%>
[6, 14] serum lipoproteins and metabolites of arachidonic acid:<br>[32, 39] biochemical risk factors for ischaemic heart disease<br>[67, 70] serum cholesterol concentrations<br>[76, 84] high density lipoprotein subfraction two (HDL2)<br>[91, 94] subfraction three (<br>[102, 106] low density lipoprotein fraction<br>[115, 129] increased plasma 6-keto-prostaglandin F1 alpha concentration and decreased serum thromboxane B2 concentration<br>[139, 142] prostaglandin E2 concentrations<br>[146, 155] increase in plasma 6-keto-prostaglandin F1 alpha concentration<br>[159, 165] increase in serum HDL2 cholesterol concentration<br>[182, 187] cholesterol distribution in serum lipoproteins<br>[198, 204] circulating metabolites of arachidonic acid.<br></td>
</tr>
